Back to top
more

Editas Medicine (EDIT)

(Real Time Quote from BATS)

$5.12 USD

5.12
512,980

+0.02 (0.39%)

Updated May 30, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA

FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.

    David Borun headshot

    Should You Buy the Dip in CRISPR Therapeutics?

    A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?

      David Borun headshot

      Is Genome Editing the Next Biotech Breakthrough?

      CRISPR technology is promising to be the foundation the treatment of 1000s of diseases

        Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

        Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?

          Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

          Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

            Kevin Cook headshot

            Why Sarepta (SRPT) Jumped and We Sold

            Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet

              Kevin Cook headshot

              Healthcare Heroes That Aren't Done Yet

              Key growth stocks across medical industries tell you the megatrends are in full force for years to come

                Editas Medicine (EDIT) Surges: Stock Moves 13.2% Higher

                Editas Medicine (EDIT) was a big mover last session, as the company saw its shares rise more than 13% on the day amid huge volumes.

                  Kevin Cook headshot

                  Bitcoin or CRISPR: Which is the Bigger Disruptor?

                  In just 5 years, two new "exponential technologies" have been created that will dramatically change the world

                    What's in the Cards for Adverum (ADVM) This Earnings Season?

                    Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                      Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%

                      Editas Medicine, Inc. (EDIT) moved big moved last session, as its shares rose over 11% on the day.

                        What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

                        Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

                          Why Editas Medicine (EDIT) Might Surprise This Earnings Season

                          Investors are always looking for stocks that are poised to beat at earnings season and Editas Medicine, Inc. (EDIT) may be one such company.

                            Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

                            Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

                              4 Drug Stocks Poised to Beat this Earnings Season

                              M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.

                                What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?

                                Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.

                                  What's in Store for BioDelivery (BDSI) this Earnings Season?

                                  BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.

                                    Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?

                                    Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11

                                      Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?

                                      Horizon Pharma plc (HZNP) is scheduled to report first-quarter 2017 results before the opening bell on May 8.

                                        What's in the Cards for Allergan (AGN) this Earnings Season?

                                        Allergan plc (AGN) will be reporting first-quarter 2017 earnings result on May 9, before the market opens.

                                          Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?

                                          Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes.

                                            Can Ligand (LGND) Spring a Surprise this Earnings Season?

                                            Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes.

                                              What to Expect from Epizyme (EPZM) This Earnings Season?

                                              Epizyme, Inc. (EPZM) is scheduled to report first-quarter 2017 results on May 8, before the opening bell.

                                                What's in Store for Adverum (ADVM) in Q1 Earnings?

                                                Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.

                                                  What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?

                                                  Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.